Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Publication
, Journal Article
Long, GV; Milhem, M; Amin, A; Hoimes, CJ; Medina, T; Conry, RM; Lao, C; Daniels, G; Reddy, S; Mehmi, I; Andtbacka, RHI; Barve, M; Shaheen, M ...
Published in: Annals of oncology : official journal of the European Society for Medical Oncology
October 1, 2018
Duke Scholars
Published In
Annals of oncology : official journal of the European Society for Medical Oncology
DOI
EISSN
1569-8041
Publication Date
October 1, 2018
Volume
29
Start / End Page
viii736
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Long, G. V., Milhem, M., Amin, A., Hoimes, C. J., Medina, T., Conry, R. M., … Ribas, A. (2018). Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, viii736. https://doi.org/10.1093/annonc/mdy424.055
Long, G. V., M. Milhem, A. Amin, C. J. Hoimes, T. Medina, R. M. Conry, C. Lao, et al. “Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii736. https://doi.org/10.1093/annonc/mdy424.055.
Long GV, Milhem M, Amin A, Hoimes CJ, Medina T, Conry RM, et al. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii736.
Long, G. V., et al. “Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Oct. 2018, p. viii736. Scopus, doi:10.1093/annonc/mdy424.055.
Long GV, Milhem M, Amin A, Hoimes CJ, Medina T, Conry RM, Lao C, Daniels G, Reddy S, Mehmi I, Andtbacka RHI, Barve M, Shaheen M, Tueting T, Chisamore M, Xing B, Candia A, Gamelin E, Janssen R, Ribas A. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii736.
Published In
Annals of oncology : official journal of the European Society for Medical Oncology
DOI
EISSN
1569-8041
Publication Date
October 1, 2018
Volume
29
Start / End Page
viii736
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis